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A disease that caused by dengue virus (DENV) has become the major health problem of the world. Nowadays, 
no effective treatment is available to overcome the disease due to the level of dengue virus pathogeneses. A 
novel treatment method such as antiviral drug is highly necessary for coping with the dengue disease. Envelope 
protein is one of the non-structural proteins of DENV, which engaged in the viral fusion process. It penetrates 
into the host cell to transfer its genetic material into the targeted cell followed by replication and establishment 
of new virus. Thus, the envelope protein can be utilized as the antiviral inhibitor target. The fusion process is 
mediated by the conformational change in the protein structure from dimer to trimer state. The previous research 
showed the existing cavity on the dimer structure of the envelope protein. The existing ligand could get into 
cavity of the envelope protein, stabilize the dimer structure or hamper the transition of dimer protein into trimer. 
In this fashion, the fusion process can be prevented. The aim of this research is designing the cyclic peptide with 
prolin-prolin bond as fusion inhibitor of DENV envelope protein through molecular docking and molecular 
dynamics simulation. The screening of 3,883 cyclic peptides, each of them connected by prolin-prolin bond, 
through molecular docking resulted in five best ligands. The pharmacological and toxicity character of these five 
ligands were analised in silico. The result showed that PYRRP was the best ligand. PAWRP was also chosen as 
the best ligand because it showed good affinity with protein cavity. Stability of ligand-protein complex was 
analyzed by molecular dynamics simulation. The result showed that PYRRP ligand was able to support the 
stability of DENV envelope protein dimer structure at 310 K and 312 K. While PAWRP ligand actively formed 
complex with the DENV envelope protein at 310 K compared to 312 K. Thus the PYRRP ligand has a potential 
to be developed as DENV fusion inhibitor. 
Keywords: dengue, envelope protein, fusion process, cavity, cyclic peptide, molecular docking, molecular 
dynamics 
1. Introduction  
 
Disease that caused by dengue virus infection has become a global health problem, especially 
in tropical and subtropical regions such as Asia, Africa, and America. This infection has 
become endemic in more than 100 countries, including Indonesia. The World Health Organ                                                                                                   
ization estimates that there have been 50-100 million cases of dengue virus infection each 
year and as many as 2.5 billion people or 40% of the world's population are at risk of 
suffering this virus infection [1]. 
 
DENV, which is a positive single-chain RNA virus, belongs to the genus flavivirus and 
family Flaviviridae. DENV has four serotypes, namely DENV-1, DENV-2, DENV-3 and 
DENV-4. Those serotypes had the same morphology and genome but show different antigens, 
thus a person can be infected more than once as there is no complete antibodies cross 
protection [2]. 
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Dengue virus RNA genome is a single strand Open Reading Frame (ORF) that encodes a 
polyprotein consisting of 3,391 amino acid residues forming three structural proteins, namely:  
C (capsid), PRM (pre-membrane), and E (envelope), and seven non-structural (NS) protein 
NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5 [3]. 
 
DENV life cycle begins with the attachment of virions to the host cell receptors and then 
enters the cell by endocytosis. The decrease in the pH of the endosome triggers the 
trimerization of Virus E protein that is irreversible and leads to the fusion process between the 
viral and host cell membranes. Through this process, the viral genome can be transferred into 
the cell. 
 
The fusion process is catalyzed by a change in condition of low pH in the endosome (~5.8-
6.0), causing a conformational change in the E dimer protein structure. Low pH condition in 
the endosome causes protonation of histidine residues that conserved in specific E protein. It 
triggers dimer protein dissociation of E structure. E protein composed of two identical chains. 
Each chain consists of three domains, they are: Domain I, N-terminal portion located at the 
tip; Domain II, the area of the fusion, and Domain III, is an area of the receptor that bind to 
the host cells (Fig. 1).  
 
The fusion process occurs at the end of the fusion peptide loop of domain II. It occurs due to 
the movement around the hinge region between domains I-II border. This exposure led to the 
entry of the fusion peptide into the host cell membrane (Fig. 2). At this transition stage, E 
protein of the virus was linked with the host cell membrane. Both membranes are close 
together while the fusion of E protein triggers the formation of trimer [4]. Previous studies 
related to the inhibition of DENV E protein by Modis et al., [5] found the existence of a 
binding region (binding pocket) on the structure of the DENV-2 E protein. This pocket is 
occupied by a detergent molecule known as n-octyl-β-D-glucoside (β-OG). Hence this pocket 
is called as β-OG pocket and located in the hinge region between the envelope protein 
domains I-II. Some related researches focused on finding inhibitors of the fusion process 
which can bind to β-OG binding pocket. The presence of the ligand occupying this site is 
expected to inhibit or prevent the process of viral-host fusion and trimerization of E protein. 
Transition of trimer formation is an important step in the entry of the dengue virus genome 
into the host cell [6,7,8]. 
 
Other related studies have also been conducted. Yennamali et al., [9] have found the cavity 
site between domains I-III on the DENV-2 E protein. The site is only found in the structure of 
dimeric E protein. The presence of a ligand that occupies this cavity stabilizes the dimer 
structure or inhibits E protein trimerization, so that the fusion process can be disturbed. This 
research focused to find a compound that can occupy this cavity through virtual screening 
methods.  
 
In our previous researches, we have designed disulfide cyclic peptide to target NS2B-NS3 
protease, RNA-dependent RNA polymerase and methyltransferase of NS5 protein of DENV 
[10, 11, 12, 13]. In this research, we designed cyclic peptides containing proline - proline 
bond and tested their affinities to target cavity of E protein via the molecular docking and 
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molecular dynamics simulations. The selection of proline residues to form cyclic peptide was 
based on the ability of the secondary amine group of proline in reducing the rotational energy 
of proline - proline mediated-cyclization [14].  
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Fig 1. DENV envelope protein dimer structure and the location of the cavity; domain I (red), domain II (yellow,) 
fusion peptide (green), and domain III (blue) 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 2. E protein trimerization process (fusion activation); (a) dimer structure, (b) trimer structure 
 
 
2. Methodology  
 
Preparation of the envelope protein (E) DENV 
 
E Protein with 1OAN_A code was downloaded from the PDB and opened in the Molecular 
Operating Environment (MOE) 2008.10. E protein structure was adjusted and optimized by 
protonate 3D option in MOE [10]. The addition of hydrogen atoms was done by selecting the 
partial charge option. Energy minimization process was conducted by using the AMBER99 
force field, gas phase solvation. The value of RMS gradient was set to 0.05 kcal / mol Å [13]. 
 
Design and preparation of cyclic peptide ligands 
 
The determination of cyclic peptide ligands as inhibitors was performed by analyzing the 
amino acid residues of the E protein cavity. The cyclic pentapeptide was formed with proline 
residues at its terminal. The combination of 7 polar amino acids (glycine, serine, threonine, 
cysteine, tyrosine, asparagine, and glutamine), 8 non polar amino acids (alanine, valine, 
leucine, isoleucine, phenylalanine, tryptophan, methionine, and proline), and 5 charged polar 
amino acids (lysine, arginine, histidine, aspartic acid, and glutamic acid) generated 3,883 
cyclic pentapeptide molecules. 
 
The process of designing 3D structure of the ligand was done by using ChemSketch 
ACDLabs. Ligand optimization and minimization was done with MOE 2008.10. Optimization 
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process was utilized by selecting the wash option and the partial charge option for all 
designed ligands. Energy minimization process was applied by using MMFF94x force field, 
gas phase solvation, and the value of RMS gradient 0.001 kcal / mol Ǻ [13]. 
 
 
Molecular Docking 
 
The docking between cyclic peptides as the ligands and E protein was done by selecting 
simulation_dock option in MOE. Triangle matcher was selected as placement method. The 
utilized scoring function is London dG. The next appearance of the 100 best pose was refined 
based on force field parameter. The displayed result of overall docking process is the best 
pose. 
 
Predicted pharmacological properties of the Ligands 
 
Prediction of the pharmacological properties of the cyclic peptides was applied to the ligands 
that came out as the best results of molecular docking. The designated pharmacological 
properties are Lipinski's Rules of five, oral bioavailability, druglikeness, and drug score. 
Predictions were performed by using Osiris Property Explorer and FAF-drugs2 software. 
 
Toxicity studies of the cyclic peptide ligands 
 
Toxicity studies were also conducted on the best ligands from molecular docking results. 
Predictive nature of the ligand carcinogenic and mutagenic properties was performed using 
software Toxtree v-2.5.0 based on Benigni and Bossa rules. The performed predictions are 
mutagenic, tumorigenic, irritant and reproductive effective characters of the ligands by using 
Osiris Property Explorer software. Analysis of the ADME-Tox (Absorption, Distribution, 
Metabolism, Excretion and Toxicity) of the ligand was performed using ACD software I-
labs/Percepta. 
 
Molecular Dynamics Simulation 
 
Optimization and energy minimization of protein-ligand complexes were required before 
performing molecular dynamics simulation. Optimization was done by selecting the partial 
charge option. Energy minimization was applied by using the AMBER99 force field and born 
solvation. The RMS gradient value was set to 0.05 kcal/molǺ. Molecular dynamics 
simulation was performed using MOE by selecting simulation_dynamic option. The utilized 
parameters were NVT ensemble and the NPA algorithm. The applied force field was 
AMBER99. 
 
3. Results and Discussion  
 
Cavity analysis of E DENV protein 
 
The cavity of E DENV protein was composed of 25 amino acid residues: residues 1, 143-149, 
156, 158, 178 and 295 of domain I, and residues 324, 333, 355-357, 359-366 of domain III [9] 
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(Fig. 3). Based on the visualization cavity with MOE, polar; uncharged polar; and non-polar 
amino acid residues selected as constituents of cyclic peptides (Fig. 4). 
 
 
 
Fig 3.Cavity visualization of E protein DENV 
 
 
Ligand screening through molecular docking process 
 
 Table 1. Five best cyclic peptide ligands according to molecular docking result 
Ligand ΔGbinding 
(Kkal/mol) 
pKi 
PYRRP -24.08 17.54 
PAWRP -20.29 14.78 
PCWRP -19.96 14.54 
PFWRP -18.94 13.79 
PWPRP -18.39 13.39 
R1 Yennamalli* -14.35 10.45 
CLREC* -12.36 9.00 
A4 Kampmann* -15.52 11.31 
A5 Kampmann* -14.69 10.69 
C6 Wang* -13.86 10.10 
NITD448 Poh* -11.567 8.423 
*: Standard 
 
Screening of 3,883 cyclic peptide ligands resulted in 5 best ligands based on the value of 
Gibbs free energy (ΔGbinding) and the value of pKi (Table 1). Based on the thermodynamic 
equation, there is a relationship between the value of the binding free energy (ΔGbinding) and 
the inhibition constant (Ki) [15]: 
 
 
 
 
 
 
Stability and strong interactions in protein-ligand complexes can be seen from the negative 
value of the Gibbs free energy of binding (ΔGbinding) that displayed on the final docking result. 
Negative values indicate that the reaction of protein-ligand complex formation takes place 
spontaneously. Ki values are shown as the mean value of the pKi, minus the value of the 
logarithm of Ki. The greater the value of pKi, the more stable the complex of protein-ligand. 
ΔGo = - RT ln KA         KA = Ki-1 =  
KA= Biological Activity constant                 [14] 
Ki = Inhibition constant                                       
7 
 
 
ICBS UGM Conference Proceeding. Yogyakarta, 20-21 September 2013. 
 
 
 
Fig 4. 2D images of the best cyclic peptide ligand screening results by molecular docking 
 
According to the value of ΔGbinding and pKi, the PAWRP and PYRRP ligands showed better 
stability and good interaction with the protein than 6 standard ligands (Table 1). Stability and 
good interaction of the complex formation can be observed from the interaction of the 
hydrogen bonds. 
 
 
The prediction of the ligand’s pharmacological properties  
 
There are four parameters of the Lipinski's rule of Five that is needed to fulfil, they are: the 
molecular weight of the molecule does not exceed 500 Da, logP value is not higher than 5, the 
number of H-donor (n OHNH) is less than 5, and the number of H-acceptor (n ON) is less 
than 10 [16]. Nonetheless, Lipinski's rule does not always serve as absolute reference for drug 
design. Generally, Lipinski's Rule of Five is applied to predict druglikeness of a molecule to 
see if it is orally active drug. 
 
Five cyclic peptide ligands (PYRRP, PAWRP, PCWRP, PFWRP, and PWPRP) did not meet 
the criteria of Lipinski's Rule. The ligands are cyclic pentapeptide whose size and molecular 
weight lie outside the range of Lipinski's rule (Table 2). Partition coefficient (logP) value is 
defined as the ratio of the concentration of a molecule in octanol and water. LogP value is 
associated with the hydrophobicity of a drug molecule. As the value of logP increases, the 
hydrophobicity character of the compound also increases. According to Lipinski's Rule, five 
cyclic peptide ligands have logP values less than 5. The nature of the ligand is influenced by 
the hydrophobicity of side chain groups of amino acid residues that make up the ligand. 
 
High oral bioavailability is an important consideration in developing bioactive molecules as 
therapeutic agents. The prediction of oral bioavailability is based on the parameters of Veber's 
rules, which includes: the number of rotatable bonds (n rotb) is 10 or fewer, topological polar 
surface area (TPSA) is less than 140 Å and the number of H-bonds (H-donor and H-acceptor) 
is less than 12. TPSA is defined as the surface area of all polar atoms of drug compound that 
is affected by oxygen (O), nitrogen (N), and hydrogen (H) atoms. TPSA values tend to be 
used as a matrix for optimization of drug traffic that penetrates the cell membrane [17].  
 
The prediction of oral bioavailability showed that all five cyclic peptide ligands have low oral 
bioavailability compared with standard ligands (Table 2). The low oral bioavailability is due 
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to the domination of polar amino acids that compose the ligands, consequently TPSA value of 
the ligands is greater than the upper limit set by Veber's rule. 
 
The drug likeness of PYRRP, PAWRP, PFWRP, PCWRP, and PWPRP ligands is greater than 
the standards. The drug score is a combination of druglikeness, logP, solubility, molecular 
weight, and toxicity risk that is used to assess the overall potential qualification of the 
compound as a drug. PYRRP, PAWRP, PCWRP, and PWPRP ligands’ drug score is greater 
than the standards. 
 
Toxicity studies of the ligand 
 
Toxtree prediction analysis showed that the ligands (PYRRP, PAWRP, PCWRP, PFWRP, 
and PWPRP) do not possess mutagenic and carcinogenic properties. It was computed based 
on QSAR (Quantitative Structure-Activity-Relationship) approach. The five ligands also did 
not have a tendency to be carcinogenic in both genotoxic and non-genotoxic levels (Table 3). 
 
The result of toxicity prediction using Osiris Property Explorer was shown by the color 
parameter; the green color indicates a low level of propensity of the parameter, while the red 
color indicates a high propensity of the parameter. Prediction results indicated that the 
PYRRP, PAWRP, and PWPRP ligands have a low tendency towards mutagenic, tumorgenic, 
irritant, or reproductive effective properties (Table 4). As for the PFWRP and PCWRP 
ligands, they have a high level of propensity to mutagenic properties. Both ligands possess 
aromatic ring of phenylalanine (F) and tryptophan (W), which is toxic to the body, on their 
amino acid residues. 
 
The result of ADME-Tox properties analysis showed that the five cyclic peptide ligands 
(PYRRP, PAWRP, PCWRP, PFWRP, and PWPRP) have side effect on the circulatory system 
and on several organs including liver, kidney and intestine. This may be due to the aromatic 
ring in the side chain groups of amino acid residues phenylalanine (F) and tryptophan (W) 
that make up the ligand. The large size of the ligands might also result in the blockage of 
arteries. Even so, the five designed cyclic peptide ligands have more toxic probabilities than 
standard ligands (Table 5). ADME-Tox analysis result also showed that oral bioavailabilty 
character of the tested ligands is low (<30%) (Table 5). This is consistent with the predictions 
of pharmacological properties based on Veber's Rules [17]. Low oral bioavailabilty requires 
the drug delivery process through injection. 
 
Table 2. The prediction of pharmacogical properties of cyclic peptide ligands  
Ligand Molecul
ar 
Weight 
(Da) 
LogP n ON n 
OHNH 
tPSA 
(Å) 
n rotb Drug 
likeness 
Drug 
score 
PYRRP 669.77 -1.07 17 12 271.95 12 9.44 0.55 
PAWRP 607,70 0.24 14 8 205.61 7 8.67 0.58 
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PFWRP 683.80 1.83 14 8 205.61 9 9.15 0.29 
PCWRP 639.77 0.16 14 8 244.41 8 4.06 0.32 
PWPRP 633.74 -0.24 14 7 196.82 7 9.09 0.56 
R1 
Yennamalli
* 
414.84 5.84 6 1 72.95 4 0.98 0.26 
A4 
Kampman* 
 
402.69 4.12 6 2 100.08 4 2.12 0.20 
A5 
Kampman* 
 
469.39 7.57 5 1 87.64 6 1.80 0.50 
C6 Wang* 428.94 5.95 4 1 78.94 5 0.29 0.08 
NITD448 
Poh* 
653.49 7.30 6 2 122.27 12 -4.44 0.05 
Note:  *= standard, n ON = the number of H-acceptor, n OHNH = the number of H-donor, n rotb = the number 
of rotatable bond. 
 
Table 3.Toxicity prediction using Toxtree 
Ligand Negative for 
genotoxic 
carcinogenicity 
Negative for 
nongenotoxic 
carcinogenicity 
Potential S. 
typhimurium 
TA100 mutagen 
based on QSAR 
Potential 
carcinogen 
based on 
QSAR 
PYRRP Yes Yes No No 
PAWRP Yes Yes No No 
PFWRP Yes Yes No No 
PCWRP Yes Yes No No 
PWPRP Yes Yes No No 
R1 
Yennamalli* 
Yes No No No 
C6 Wang* Yes No No No 
A4 
Kampmann* 
Yes Yes No No 
A5 
Kampmann* 
No No No No 
NITD448 Poh* No Yes No No 
Note:  *: standard  
 
Table 4. Toxicity prediction analysis of the cyclic peptide ligands using Osiris Property Explorer 
 
Ligand 
Mutagenic Tumorgenic Irritant 
Reproductive 
effective 
PYRRP Green Green Green Green 
PAWRP Green Green Green Green 
PFWRP Red Green Green Green 
PCWRP Red Green Green Green 
PWPRP Green Green Green Green 
R1 Yennamalli* Green Green Green Green 
C6 Wang* Green Yellow Green Green 
A4 Kampmann* Green Green Yellow Green 
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A5 Kampmann* Yellow Red Green Green 
NITD448 Poh* Green Green Red Green 
Note:  *: standard 
 
Table 5. ADME-Tox properties prediction of the cyclic peptide ligands using ACD I-Lab 
Parameter PYRRP PAWRP PFWRP PCWRP PWPRP 
Oral 
Bioavailibility 
Less than 30% Less than 30% Less than 30% Less than 30% Less than 30% 
Health Effects:      
Blood 1.00 1.00 1.00 1.00 0.96 
Cardiovascular 0.36 0.97 0.63 0.98 1.00 
Gastrointestinal 0.90 0.96 1.00 0.98 0.97 
Kidney 0.99 1.00 1.00 1.00 1.00 
Liver 0.99 1.00 1.00 0.99 0.99 
Lungs 0.89 0.84 0.96 0.96 0.89 
Probability of 
Toxicity 
 
No 
(94% 
probability non-
toxic) 
Yes 
(80% 
probability 
harmful) 
Yes 
(78% 
probability 
harmful) 
Yes (85% 
probability 
hazard and 
harmful) 
Yes 
(80% 
probability 
harmful) 
PGP Inhibitor No No No No No 
CNS active  No No No No No 
Active 
Transport : 
     
Pep T1 Not Transported Not Transported Not Transported Not Transported Not 
Transported 
ASBT Not Transported Not Transported Not Transported Not Transported Not 
Transported 
 
Based on the molecular docking, pharmacological and toxicological properties prediction, the 
PYRRP and PAWRP ligands serve as the best ligand to target DENV envelope protein. This 
ligands were then proceeded to for molecular dynamics simulation. 
 
The results of molecular dynamics simulations 
 
Molecular dynamics simulation was used to analyze the conformational changes in the 
protein-ligand complex due to the influence of implicit solvent into the system. Therefore, the 
protein and ligand flexibility was set to born solvation [18]. 
 
There are three stages in the molecular dynamics simulations; the initialization, equilibration, 
and production stage. In the initialization phase, the initial state of the system was determined, 
including atomic coordinate, velocity and potential energy of the system.  
 
Initialization phase was done at a temperature of 300 K for 100 ps. The simulation was run 
until the system reached equilibration point that was indicated by the decline in the potential 
energy of system in order to achieve stability [19]. Production stage of the simulation 
produced trajectory. The obtained trajectory is a coordinate that was formed by taking the data 
changes in the state of each atom versus time due to the influence of temperature. 
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Fig 5 Initialization curve of E protein-ligand PYRRP complexes 
 
In the protein-ligand complexes, the fluctuation was started from 0 ps to 30 ps for PYRRP 
ligand (Fig. 5), whereas for ligand PAWRP the fluctuation was started from 0 ps to 28 ps 
(Fig. 6). The time required to reach the equilibration point were 30 ps for PYRRP protein-
ligand complexes and 28 ps for PAWRP protein-ligand complexes. After reaching the point 
of equilibration, both protein-ligand complexes were able to adjust the conformation with the 
implicit solvent. 
 
 
Fig 6. Initialization curve of E protein-ligand PAWRPP complexes 
 
The second stage of the production of protein-ligand complexes (PYRRP and PAWRP) was 
performed at 310 K and 312 K, which represents normal and fever body temperature, 
respectively. The production stage is divided into three stages, namely heating, the main 
simulation, and cooling. The heating and cooling stages were conducted to find the lowest 
energy conformation of the complex. 
 
The result of the production phase at 310 K indicated that the two ligands, PYRRP and 
PAWRP, retained the hydrogen bond interaction with the envelope cavity until the end of the 
cooling stage. During the early stage of initialization until the end of 5000 ps simulation stage, 
the PYRRP and PAWRP ligands still interacted with the binding site residues of envelope 
protein cavity. Formation of hydrogen bonds between the ligands and the protein cavity 
during the dynamics simulation occurred in several ways, namely through interaction with the 
ligand’s side chain and the backbone of the protein cavity (Table 6). 
 
The result of the production phase at 312 K also showed that both ligands, PYRRP and 
PAWRP, also retained interaction with the cavity on the DENV envelope protein until the end 
of the cooling stage. During the initialization process until the end of 5000 ps simulation 
12 
 
 
ICBS UGM Conference Proceeding. Yogyakarta, 20-21 September 2013. 
 
stage, the PAWRP and PYRRP binding position were remain consistent with the binding site 
residues of envelope protein cavity. Hydrogen bonds between the PYRRP ligand and Glu 
A360, Asp A362, and Ser A363 residues of the envelope cavity remained stable until the end 
of the simulation. PAWRP also maintained its imteraction with Glu A360 and A147 residuess 
of the envelope cavity until the end of simulation (Table 7).  
 
 
Table 6. Hydrogen bonds of the complex during molecular dynamics simulation at 310K 
Ligand 
 
Steps 
PYRRP PAWRP 
Initialization Glu A360, Glu A360, Glu A360, Glu 
A360, Asp A362, Asp A362, Asp 
A362 
Glu A360, Glu A360, Lys A157 
Heating 10 ps Glu A360, Glu A360, Glu A360, Asp 
A362, Ser A363 
Glu A147, Glu A148, Glu A360 
Simulation 5000 ps His A158, His A158, Lys A295, Lys 
A295, Asp A329, AspA329, Glu 
A360, Glu A360, Glu A360, Lys 
A361, Lys A361, Asp A362, Asp 
A362, Asp A362, Thr A359, Glu 
A360, Glu A360, Glu A360, Ser 
A363 
Glu A148, Glu A148, Glu A148, 
His A149, Lys A295 
 
Cooling 10 ps 
His A158, His A158, Lys A295, Lys 
A295, Asp A329, Asp A329, Thr 
A359, Thr A359, Glu A360, Glu 
A360, Glu A360, Glu A360, Lys 
A361, Lys A361, Asp A362, Asp 
A362, Asp A362, Ser A363 
Glu A148, Glu A148, His A149, 
His A149, Lys A295 
 
 
Table 7. Hydrogen bonds of the complex during molecular dynamics simulation at 312K 
Ligand 
PYRRP PAWRP  
Steps 
Initialization Glu A360, Glu A360, Glu A360, Glu 
A360, Asp A362, Asp A362, Asp A362 
Glu A360, Glu A360, Lys 
A157 
Heating 10 ps Glu A360, Glu A360, Glu A360, Asp 
A362, Ser A363 
Glu A147, Glu A148, Glu 
A360 
Simulation 5000 ps Glu A147, Glu 360, Glu A360, Glu 360, 
Ser A363 
Glu A147, Glu 360, Glu 
A360, Glu 360 
13 
 
 
ICBS UGM Conference Proceeding. Yogyakarta, 20-21 September 2013. 
 
 
Cooling 10 ps 
Glu A147, Glu A147, Gly A177, Ser 
A363, Thr A359, Glu A360, Glu A360, 
Glu A360  
Glu A147, Glu 360, Glu 
A360, Glu 360 
 
Note : Residues in red are the binding sites of DENV E protein cavity 
 
The magnitude of the protein-ligand complex conformational changes due to the influence of 
implicit solvent and temperature can be studied from the curve of its simulation time versus 
RMSD (Root Mean Square Deviation). 
 
 
Fig 7. The relation between RMSD value of protein-ligand PYRRP complex and time steps during the 5000-ps-
molecular–dynamics-simulation 
 
The RMSD curve of protein-PYRRP complex showed that there were fluctuations during 
1000-1500 ps simulation at 310 K. However, the complex maintained its stability at 310 K 
and 312 K in the interval of 2500-5000 ps simulation (Fig. 7). Hence, the PYRRP ligand was 
able to maintain a stable interaction with the envelope cavity at both tested temperature. 
 
 
Fig 8. The relation between RMSD value of protein-ligand PAWRP complex and time steps during the 5000-ps-
molecular–dynamics-simulation 
 
RMSD curve of protein- PAWRP complex at 312 K has a smaller RMSD value than it has at 
310 K. This suggests that there are more conformational changes of complex occur at 310 K 
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rather than at 312 K. Therefore, the complex between PAWRP and envelope protein is more 
stable at 310 than at 312 K. 
 
4. CONCLUSION 
 
The screening by means of molecular docking process generated five ligands (PYRRP, 
PAWRP, PCWRP, PFWRP, and PWPRP) which have better affinity (as indicated by their 
ΔGbinding and pKi) with envelope cavity than the standards. Based on pharmacological and 
toxicological prediction analysis, PYRRP and PAWRP were the best ligands among all. 
During molecular dynamics simulation, both ligands were able to maintain interaction with 
DENV envelope protein cavity until the end of 5000-ps-simulation, either at 310 K or at 312 
K. It was indicated from RMSD analysis that the PYRRP ligand was able to maintain the 
stability of protein-ligand complex at both tested temperature, while the PAWRP ligand was 
more reactive at 310 K than at 312 K. Therefore, PYRRP ligand has potential to be developed 
further as a DENV fusion inhibitor. 
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